Bisphosphonates in breast cancer: teaching an old dog new tricks

The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response – exploratory evidence for direct anti-tumor activity in breast cancer.

(2010) MC Winter et al.   CANCER RESEARCH

The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST.

(2010) H Eidtmann et al.   CANCER RESEARCH

Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE).

(2010) C Van Poznak et al.   CANCER RESEARCH

Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients.

(2010) E Solomayer et al.   CANCER RESEARCH

Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results

(2009) Adam M. Brufsky et al.   Clinical Breast Cancer

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

(2009) Michael Gnant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer

(2008) Bent Kristensen et al.   ACTA ONCOLOGICA

Practical guidance for the management of aromatase inhibitor-associated bone loss

(2008) P. Hadji et al.   ANNALS OF ONCOLOGY

Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow--a long-term follow-up

(2008) I. J. Diel et al.   ANNALS OF ONCOLOGY

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan

(2008) C. I. Ripamonti et al.   ANNALS OF ONCOLOGY

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

(2008) Nigel J. Bundred et al.   CANCER

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

(2008) Allan Lipton et al.   CANCER

Exploring the anti-tumour activity of bisphosphonates in early breast cancer

(2008) M.C. Winter et al.   CANCER TREATMENT REVIEWS

Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group

(2008) David M. Reid et al.   CANCER TREATMENT REVIEWS

Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer

(2008) J. E. Lester et al.   CLINICAL CANCER RESEARCH

Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates

(2008) Ana O Hoff et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230

(2008) Richard Eastell et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer

(2008) Stephanie L. Hines et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Effects of Doxorubicin Followed by Zoledronic Acid in a Mouse Model of Breast Cancer

(2008) P. D. Ottewell et al.   JNCI-Journal of the National Cancer Institute

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

(2008) Michael Gnant et al.   LANCET ONCOLOGY